Guangdong / Biomedicine Company Structure Study

Comparative structure study

The largest recorded chain role, Biomedicine and medical devices / Complete systems and use-case applications, contains 85 records (82.5% of this 103-record cohort). Companies may carry multiple labels in this dimension; participation rates are not additive market shares.

The recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications accounts for 82.5% here (85/103), compared with 75.1% in the parent set (1,292/1,721), an absolute gap of 7.5 percentage points.

24/103 companies link to pages with existing source-supported excerpts (23.3% of the cohort). The other 79 records remain usable for archive composition, but do not support new operating case studies.

An ID-deduplicated archive snapshot, not the whole market, current recognition or operating results.

The parent set, Biomedicine, contains 1,721 records. This cohort contributes 103 (6.0%); 1,618 records remain after excluding it.

The parent set, Guangdong, contains 1,382 records. This cohort contributes 103 (7.5%); 1,279 records remain after excluding it.

Ratio of label participation, not market share; multi-label counts overlap.

Excluding this cohort, the recorded chain role label Biomedicine and medical devices / Complete systems and use-case applications covers 1,207/1,618 remaining records (74.6%), an absolute gap of 7.9 percentage points from this cohort.

Record counts do not rank supply capability or economic size.

Non-empty fields are not necessarily accurate or supported by originals.

Counts concern existing reviewed bilingual excerpts, not re-certification of originals or entire reports.

A rule hit prioritises review; it does not establish that the entire field is wrong. One record can trigger several rules.

25 of this cohort’s 103 records link through existing company-ID mappings to 2026 lists from all jurisdictions (24.3%). This intersection measures list linkage, not successful recognition or company growth.

List rows and company IDs are separate counts, not new firms or final recognition.

The 2025 macro context for Guangdong uses a different denominator from this cohort.

Drug-production leads need validation and change records

The Chemical drugs and formulations label covers 9 records (8.7% of this cohort). This archive clue raises a verification question about Defined pharmaceutical-production or testing services with quality documents; it does not establish that these companies already deliver it.

Shared records with Guangdong / Biomedicine and medical devices / Complete systems and use-case applications Company Structure Study: 85; records in this cohort but outside that set: 18. The intersection/union ratio is 78.7%, a measure of label overlap rather than business collaboration. Read comparison

Shared records with Guangdong Company Archive Study: 103; records in this cohort but outside that set: 0. The intersection/union ratio is 7.5%, a measure of label overlap rather than business collaboration. Read comparison

Stable-ID samples, not rankings; metrics use the full cohort.